CTSB and plasma cell myeloma: Our research illustrated that increased calcium/cathepsin B activation/trypsinogen activation might be one of the mechanisms underlying acute pancreatitis induced by the proteasome inhibitor Bortezomib or Ixazomib in patients with multiple myeloma.